Skip to main content
Top
Published in: Neurological Sciences 1/2010

01-02-2010 | Original Article

Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis

Authors: Alberto Raggi, Matilde Leonardi, Carlo Antozzi, Paolo Confalonieri, Lorenzo Maggi, Ferdinando Cornelio, Renato Mantegazza

Published in: Neurological Sciences | Issue 1/2010

Login to get access

Abstract

Aim of this study is to verify whether there is concordance between disease’s severity, health-related quality of life (HRQoL) and disability in patients with Myasthenia gravis (MG). 102 MG patients were clustered on the basis of HRQoL and disability scores into three groups: low disability and low HRQoL decrement (51 patients), intermediate disability and HRQoL decrement (28 patients), severe disability and high HRQoL decrement (23 patients). Cross tabulation with symmetric measures (Cramer’s V and Contingency Coefficient) was used to verify the relationships between disease severity groups, based on the Myasthenia Gravis Foundation of America (MGFA) criteria, and obtained clusters. Results confirm a significant relationship between MG severity groups, HRQoL and disability profiles. In our opinion, HRQoL and disability instruments should be employed in clinical trials to match efficacy of treatments, measured on symptoms’ reductions only, with their effects on patients’ disability and HRQoL.
Literature
1.
go back to reference Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, future. J Clin Invest 116:2843–2854CrossRefPubMed Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, future. J Clin Invest 116:2843–2854CrossRefPubMed
2.
go back to reference Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23PubMed Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23PubMed
4.
go back to reference Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 998:413–423CrossRefPubMed Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 998:413–423CrossRefPubMed
5.
go back to reference Barohn RJ, Mcintire D, Herbelin L, Wolfe GI, Nations S, Bryan W (1998) Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 941:769–772CrossRef Barohn RJ, Mcintire D, Herbelin L, Wolfe GI, Nations S, Bryan W (1998) Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 941:769–772CrossRef
6.
go back to reference Pauda L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, Tonali P (2001) Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 22:363–369CrossRef Pauda L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, Tonali P (2001) Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 22:363–369CrossRef
7.
go back to reference Paul RH, Nash J, Cohen RA, Gilchrist JM, Goldstein JM (2001) Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 24:512–516CrossRefPubMed Paul RH, Nash J, Cohen RA, Gilchrist JM, Goldstein JM (2001) Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 24:512–516CrossRefPubMed
8.
go back to reference Padua L, Evoli A, Aprile I, Caliandro P, D’Amico P, Rabini A, Tonali P (2002) Quality of life in patients with myasthenia gravis. Muscle Nerve 25:466–467CrossRefPubMed Padua L, Evoli A, Aprile I, Caliandro P, D’Amico P, Rabini A, Tonali P (2002) Quality of life in patients with myasthenia gravis. Muscle Nerve 25:466–467CrossRefPubMed
9.
go back to reference Rostedt A, Padua L, Stålberg EV (2006) Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol 13:191–193CrossRefPubMed Rostedt A, Padua L, Stålberg EV (2006) Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol 13:191–193CrossRefPubMed
10.
go back to reference Rostedt A, Padua L, Stalberg EV (2005) Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in Myasthenia Gravis patients. Clin Neurophysiol 116:2058–2064CrossRefPubMed Rostedt A, Padua L, Stalberg EV (2005) Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in Myasthenia Gravis patients. Clin Neurophysiol 116:2058–2064CrossRefPubMed
11.
go back to reference Scott KR, Kothari MJ (2006) Self-reported pain affects quality of life in Myasthenia Gravis. J Clin Neuromusc Dis 7:110–114CrossRef Scott KR, Kothari MJ (2006) Self-reported pain affects quality of life in Myasthenia Gravis. J Clin Neuromusc Dis 7:110–114CrossRef
12.
go back to reference Happe S, Klosch G, Zeitlhofer J (2004) Perception of dreams and subjective sleep quality in patients with myasthenia gravis. Neuropsychobiology 50:21–27CrossRefPubMed Happe S, Klosch G, Zeitlhofer J (2004) Perception of dreams and subjective sleep quality in patients with myasthenia gravis. Neuropsychobiology 50:21–27CrossRefPubMed
13.
go back to reference Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400–406CrossRefPubMed Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400–406CrossRefPubMed
14.
go back to reference Rostedt A, Padua L, Stalberg EV (2006) Validation of the Swedish version of the disease-specific Myasthenia Gravis Questionnaire. Neurol Sci 27:91–96CrossRefPubMed Rostedt A, Padua L, Stalberg EV (2006) Validation of the Swedish version of the disease-specific Myasthenia Gravis Questionnaire. Neurol Sci 27:91–96CrossRefPubMed
15.
go back to reference Padua L, Galassi G, Ariatti A, Aprile I, Caliandro P, Evoli A, Pazzaglia C, Tonali P (2005) Myasthenia gravis self-administered questionnaire: development of regional domains. Neurol Sci 25:331–336CrossRefPubMed Padua L, Galassi G, Ariatti A, Aprile I, Caliandro P, Evoli A, Pazzaglia C, Tonali P (2005) Myasthenia gravis self-administered questionnaire: development of regional domains. Neurol Sci 25:331–336CrossRefPubMed
16.
go back to reference Mullins LL, Carpentier MY, Paul RH, Sanders DB, Muscle Study Group (2008) Disease-specific measure of quality of life for Myasthenia Gravis. Muscle Nerve 38:947–956CrossRefPubMed Mullins LL, Carpentier MY, Paul RH, Sanders DB, Muscle Study Group (2008) Disease-specific measure of quality of life for Myasthenia Gravis. Muscle Nerve 38:947–956CrossRefPubMed
17.
go back to reference Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group (2008) Less is more, or almost as much: a 15-item quality of life instrument for myasthenia gravis. Muscle Nerve 38:957–963CrossRefPubMed Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group (2008) Less is more, or almost as much: a 15-item quality of life instrument for myasthenia gravis. Muscle Nerve 38:957–963CrossRefPubMed
18.
go back to reference Leonardi M, Bickenbach J, Ustun TB, Kostanjsek N, Chatterji S, MHADIE Consortium (2006) The definition of disability: what is in a name? Lancet 368:1219–1221CrossRefPubMed Leonardi M, Bickenbach J, Ustun TB, Kostanjsek N, Chatterji S, MHADIE Consortium (2006) The definition of disability: what is in a name? Lancet 368:1219–1221CrossRefPubMed
19.
go back to reference World Health Organisation (2001) The international classification of functioning, disability and health-ICF. WHO, Geneva World Health Organisation (2001) The international classification of functioning, disability and health-ICF. WHO, Geneva
20.
go back to reference Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036CrossRefPubMed Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036CrossRefPubMed
21.
go back to reference Ustun TB (1999) WHO-DAS II Field Trials Report 1998. WHO, Geneva Ustun TB (1999) WHO-DAS II Field Trials Report 1998. WHO, Geneva
22.
go back to reference Bedlack RS, Simel DL, Bosworth H, Samsa B, Tucker-Lipscomb B, Sanders DB (2005) Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 64:1968–1970CrossRefPubMed Bedlack RS, Simel DL, Bosworth H, Samsa B, Tucker-Lipscomb B, Sanders DB (2005) Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 64:1968–1970CrossRefPubMed
23.
go back to reference Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F (1988) Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 255:449–453CrossRef Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F (1988) Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 255:449–453CrossRef
24.
go back to reference Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, Houfani M, Gajdos P (2000) Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 247:286–290CrossRefPubMed Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, Houfani M, Gajdos P (2000) Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 247:286–290CrossRefPubMed
25.
go back to reference Wolfe GI, Herbelin LR, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487–1489PubMed Wolfe GI, Herbelin LR, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487–1489PubMed
26.
go back to reference Vanderveldea L, Van den Bergh PYK, Goemans N, Thonnard JL (2007) ACTIVLIM: a Rash-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord 17:459–469CrossRef Vanderveldea L, Van den Bergh PYK, Goemans N, Thonnard JL (2007) ACTIVLIM: a Rash-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord 17:459–469CrossRef
Metadata
Title
Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis
Authors
Alberto Raggi
Matilde Leonardi
Carlo Antozzi
Paolo Confalonieri
Lorenzo Maggi
Ferdinando Cornelio
Renato Mantegazza
Publication date
01-02-2010
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 1/2010
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-009-0167-y

Other articles of this Issue 1/2010

Neurological Sciences 1/2010 Go to the issue